All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Biohaven Ltd. has acquired global rights, excluding China regions, from Hangzhou Highlightll Pharmaceutical Co. Ltd. for TLL-041, now designated BHV-8000, an oral, brain-penetrant, highly selective, dual TYK2/JAK1 inhibitor, for neurological disorders.
Coimmune Inc. has exercised its option to obtain an exclusive license to IL-18 armored chimeric antigen receptor (CAR) technology under a prior agreement with Memorial Sloan Kettering Cancer Center (MSK). The company plans to couple the technology with allogeneic cytokine induced killer (CIK) cells to launch the clinical development of CMN-008 (armored CAR-CIK cells), with CD19 as the initial target in B-cell malignancies.
Gilead Sciences Inc. has exercised its option to exclusively license Nurix Therapeutics Inc.'s investigational targeted protein degrader molecule NX-0479, now designated GS-6791. This bivalent degrader is the first development candidate resulting from the companies' collaboration to discover, develop and commercialize up to five innovative targeted protein degradation therapies.
Eureka Therapeutics Inc. has entered into a license agreement with the National Cancer Institute (NCI) to develop and commercialize a novel antibody targeting mesothelin (MSLN) in combination with Eureka's proprietary Artemis T-cell receptor platform.
Modex Therapeutics Inc., an Opko Health Inc. company, has entered into an exclusive worldwide license and collaboration agreement with Merck & Co. Inc., for the development of MDX-2201, Modex's preclinical nanoparticle vaccine candidate targeting Epstein-Barr virus (EBV).
Coya Therapeutics Inc. has announced expansion of its exclusive worldwide rights for the development and commercialization of COYA-301, the company's low-dose IL-2 subcutaneous administration product candidate. COYA-301 is intended to enhance regulatory T-cell (Treg) function in vivo to treat the systemic neuro-inflammation underlying certain autoimmune and neurodegenerative diseases.
Calibr at Scripps Research and the Bill & Melinda Gates Medical Research Institute (Gates MRI) have entered into a strategic licensing agreement to advance development of a novel investigational compound for treatment of tuberculosis (TB).
Thylacine Biotherapeutics Inc. has entered into a license agreement with Columbia University for worldwide exclusive rights to develop and commercialize a novel antiviral peptide platform invented and refined at Columbia.
Tonix Pharmaceuticals Holding Corp. has exercised an option to obtain an exclusive license from Columbia University for the development of a portfolio of fully human (TNX-3600) and murine (TNX-4100) monoclonal antibodies for the treatment or prophylaxis of SARS-CoV-2 infection.
Legochem Biosciences Inc. has entered into a license agreement with Elthera AG to develop and commercialize a novel antibody-drug conjugate (ADC) therapy using a monoclonal antibody developed by Elthera.
RSS
